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INTRODUCTION
Inappropriate prescribing of analgesics or self-administration through over the counter
formulations results in regular often negative reporting within the media. Indeed, their abuse
within elite through to recreational sport is not uncommon (Feucht and Patel, 2010; Warden, 2010;
Tscholl and Dvorak, 2012; Brewer et al., 2014). For example, acetaminophen (ACT; commonly
known as paracetamol) use is even prevalent in young sub-elite athletes, who consume ACT or
other analgesics [e.g., non-steroidal anti-inflammatory drugs (NSAIDs)] to decrease pain from
previous athletic exertion or prophylactically to reduce pain in subsequent training/competition
(Garcin et al., 2005). Related recent headlines include a former FIFA Chief Medical Officer stating
that “about half of players competing at the past three World Cups routinely took NSAIDs
like ibuprofen” whilst former players report pressure to use such drugs “to get through games”
(BBCSport, 2017). NSAIDs and ACT are the most commonly used antipyretic and analgesic drugs
worldwide (Hinz and Brune, 2012). Given they are available over the counter, their use even
with careful club/team physician oversight can be difficult to police within a professional sport
environment. If team clinicians ban over the counter analgesia use, players can and do simply
self-administer, increasing risk of drug interaction with clinician prescribed medications and/or
over-dose risk (inadvertently or otherwise).
ACT has been used globally since 1955 and is considered a safe effective analgesic
(Bunchorntavakul and Reddy, 2013). The analgesic properties of ACT are similar to NSAIDs, yet
ACT does not share similar NSAID mediated anti-inflammatory actions (Graham et al., 2013).
ACT carries fewer, if any, side-effects when used at appropriate dosages compared to NSAIDs
(Towheed et al., 2006; Jones et al., 2015). NSAIDs side-effects can include gastrointestinal and
arterial wall damage, gastrointestinal ulcers, arterial blood clotting, myocardial infarction, stroke
and hemorrhage perforation, amongst others (Ong et al., 2007; Van Wijck et al., 2012). The well
evidenced and publicized side-effect of ACT is liver necrosis in cases of acute overdose [e.g., ACT
at 250mg.kg, ∼15 g for a 60 kg human (Prescott et al., 1971; Prescott, 1980; Raffa et al., 2014)],
evidently not seen under appropriate acute and/or regular use (Skoglund et al., 1991; Dippel et al.,
2003a). Although uncommon relative to ACT chronic use, liver necrosis has been reported when
concomitant with other factors such as fasting/malnutrition, alcoholism and the use of cytochrome
P450 enzyme inducing drugs (Vitols, 2003).
Novel research has seen ACT used outside of its typical clinical parameters, including exercise
performance domains (Mauger et al., 2010, 2014; Foster et al., 2014) and to induce mild
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hypothermia within afebrile humans (Foster et al., 2016, 2017).
ACT use whilst safe in many scenarios (Ong et al., 2007; Graham
et al., 2013) does present risk in others (Hinz and Brune, 2012;
Aminoshariae and Khan, 2015), across research and clinical
agendas. This opinion piece will detail the variable acute dose
and chronic dosages, and their pharmacological safety across
established and emerging research fields. In particular, this article
will present evidence to support the following opinions:
(1) ACT should not be advocated for use within a sporting
context, given the present evidence is from tightly
controlled laboratory studies which do not replicate the
multifaceted physiological, biochemical, and environmental
perturbations to homeostasis during sporting performance.
(2) ACT may provide a useful tool in determining fundamental
biochemical thermoregulatory mechanisms in vivo in




Evidence presented/discussed herein focuses on orally
administered ACT in adult populations (unless stated otherwise).
An “acute” ACT dose constitutes one-time single administration,
whilst a chronic ACT “dosage” describes multiple doses over a
day(s). An adult therapeutic dose of ACT is a 1 g single dose
or a dosage of 4 ∗ 1 g daily at 4–6 h intervals (Bunchorntavakul
and Reddy, 2013). Children aged 2–12 years are normally
given an individualized body weight derived therapeutic dose
at 10–15mg.kg (Jackson et al., 1984). ACT has been used
beyond its primary functions as an analgesic and antipyretic
in attempts to understand or augment athletic performance
(Mauger et al., 2010, 2014; Mauger and Hopker, 2012; Foster
et al., 2014) and manipulate/characterize thermoregulation
within temperate, cold and hot environments (Dippel et al.,
2001, 2003b; Coombs et al., 2015; Taylor et al., 2015; Foster et al.,
2016, 2017). From these specific fields of research, no evidence
of adverse reactions to ACT have been reported. The evidence
informed safety of ACT from seminal work across a variety of
populations will be discussed later in this article (see ACT dose
and pharmacokinetics section).
An acute ≤ 1.5 g ACT dose has been used in athletic
performance research to improve time trial, time to exhaustion
and repeated sprint exercise performance (Mauger et al., 2010,
2014; Mauger and Hopker, 2012; Foster et al., 2014). These effects
were attributed to ACT-mediated reductions in exercise induced
pain, resulting in maintenance of a higher power output and/or
an increased time to exhaustion, despite no change in perceived
pain or exertion compared to a placebo condition (Mauger et al.,
2010, 2014; Foster et al., 2014). Whilst tolerance of exercise
induced pain can be crucial to athletic performance (Ayoub
et al., 2004; Amann et al., 2009; Astokorki and Mauger, 2017a,b),
it also serves to provide essential feedback on injury and/or
fatigue [i.e., a deterrent/modulator of an activity potentially
causative of harm (Mauger, 2013)]. Indeed, complete inhibition
of pain elicited adoption of an over-aggressive sub-optimal
cycling pacing strategy resulting in greater peripheral fatigue
and no improvement in athletic performance, without injury
pesentation (Amann et al., 2009). This suggests that pain may
provide valuable feedback to higher centers to maintain an
“optimal” distribution of work rate (Ayoub et al., 2004; Astokorki
and Mauger, 2017a,b; St Clair Gibson et al., 2017).
Disruption of thermoregulatory mechanisms by ACT have
been linked to improved time to exhaustion during cycling
exercise in the heat (Mauger et al., 2014). Attributed to
core temperature (Tc), skin temperature, body temperature
and thermal sensation being significantly reduced in the ACT
compared to placebo condition (Mauger et al., 2014). This
suggests ACT disrupted thermoregulatory mechanisms and
reduced thermal strain during exercise (Mauger et al., 2014),
as observed elsewhere (Burtscher et al., 2013; Veltmeijer et al.,
2016). These specific thermoregulatory effects of ACT may,
or may not, have been complemented by the analgesic effects
discussed above (Mauger et al., 2010; Foster et al., 2014). It must
be stated here that the above exercise performance discussions
are not advocating the use of ACT within these domains.
The clinician and athlete (elite or otherwise) together should
deliberate the ethical and safety considerations of strategies that
override homeostatic controls before implementing them to
enhance exercise performance, or indeed for any other purpose
(clinically or otherwise).
ACT can alter thermoregulation in clinical (Dippel et al., 2001,
2003b; Koennecke and Leistner, 2001; Kasner et al., 2002) and
healthy populations (Foster et al., 2016, 2017). Up to half of
patients who suffer an acute stroke present with a febrile Tc
(Dippel et al., 2001). ACT administration elicited dose dependent
Tc reductions of 0.4◦C [6 ∗ 1 g/day for 5 days (Dippel et al.,
2001, 2003b)] and 0.22◦C [3.9 g/day for 5 days (Kasner et al.,
2002)] in these patients. ACT ingestion [20mg.kg lean body
mass (LBM)] inducedmild hypothermia (range: 0.1–0.39◦C drop
in Tc) in afebrile participants housed in ambient conditions of
20◦C 40% relative humidity [RH (Foster et al., 2016)]. Such
conditions are below the human thermoneutral zone (TNZ)
where the body invokes mechanisms to maintain a stable Tc
(Stocks et al., 2004). Within a similar design to Foster et al.
(2016), Foster et al. (2017) demonstrated within cold (10◦C 40%
RH) compared to thermoneutral conditions (25◦C 40% RH),
ACT ingestion (20mg.kg LBM) elicited Tc instability (Foster
et al., 2017). Specifically, Tc decreased in the cold condition
(10◦C 40% RH) with ACT ingestion (range: 0.16–0.57◦C) and
remained stable within the cold placebo condition whilst Tc
stability was maintained in both placebo and ACT thermoneutral
conditions (25◦C 40%RH). This in vivo human data suggest ACT
has inhibitory actions on heat producing mechanisms in certain
febrile (Dippel et al., 2001, 2003b; Koennecke and Leistner, 2001;
Kasner et al., 2002) and afebrile states (Foster et al., 2016, 2017).
Within afebrile states the limited data suggests hypothermic
effects present only below the human TNZ (Foster et al., 2016,
2017).
Mechanistically it appears ACT has an ability to disrupt
“normal” thermoregulatory mechanisms in humans beneath
the TNZ (Foster et al., 2016, 2017). This is outside ACT’s
typical use as an analgesic and febrile antipyretic. Indeed, whilst
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explicitly described within rodents (Langenbach et al., 1995;
Ayoub et al., 2004), the cyclooxygenase (COX)-prostaglandin E2
(PGE2) thermogenesis pathway (detailed below) has not been
robustly determined in vivo within humans. COX1 knockout
mice produced 99% less PGE2 than their wild type counterparts
(Langenbach et al., 1995). No compensatory COX2 production
to maintain PGE2 levels occurred when inflammation was not
present (Langenbach et al., 1995). Such data indicate that PGE2
production, and thus thermogenesis, is somewhat dependent
upon COX1 in the absence of a febrile and/or inflammatory
state. Confirming the thermogenic influence of this COX1-PGE2
pathway in afebrile and non-inflammatory mammal’s, housed
beneath their TNZ, is a robust dose dependent drop in Tc within
wild type mice [i.e., not COX1 knockout mice (Ayoub et al.,
2004; Fukushima et al., 2017)]. ACT administration in the largest
doses (300 mg.kg) produced the greatest Tc decreases [2 and
4◦C (Ayoub et al., 2004; Fukushima et al., 2017)], and a 96%
reduction in PGE2 concentrations (Ayoub et al., 2004). There is
uncertainty within the literature on the function of a third COX
isoform within mammals, a splice variant of COX1, COX3. This
data suggests that COX3 could be the primary target of ACT
(Botting, 2000; Chandrasekharan et al., 2002; Botting and Ayoub,
2005). These COX1-3 (Chandrasekharan et al., 2002; Botting
and Ayoub, 2005) and/or PGE2 (Langenbach et al., 1995; Ayoub
et al., 2004) results were generalized to humans without specific
evidence (Kis et al., 2005) given the analgesic and antipyretic
functions of ACT are closely related to COX2 inhibition (Graham
and Scott, 2005; Graham et al., 2013). The human specific general
consensus within the literature, is that the inhibition of COX
isoforms, COX1 (maintains homeostasis) and COX2 [combats
pathophysiological states including inflammation, pain and fever
(Fitzpatrick, 2004; Hinz et al., 2008; Rouzer and Marnett,
2009; Hinz and Brune, 2012; Graham et al., 2013; Józwiak-
Bebenista and Nowak, 2013)] alter “normal” thermoregulatory
physiological responses/controls. Yet this consensus is derived
from rodents, albeit robustly (Langenbach et al., 1995; Ayoub
et al., 2004), and not substantiated in vivo in humans. Research
to confirm such consensus in humans is paramount given the
wide variance of responses to ACT observed between and even
within species (different strains) of laboratory animals (Bessems
and Vermeulen, 2001). In light of the evidence from Foster
et al. (2016), Foster et al. (2017) and related hypotheses (Foster
et al., 2015) future well-controlled experimental trials, in vivo in
humans, utilizing ACT to inhibit COX could characterize COX1-
3 and PGE2 concentrations and their mechanistic relationship
with thermogenesis.
Given the increasing prevalence of research conducted using
ACT outside of its typical functions (Mauger et al., 2010, 2014;
Mauger and Hopker, 2012; Foster et al., 2014, 2016, 2017;
Coombs et al., 2015) the matter of pharmacological safety is
current, relevant and important. A plethora of evidence is
available highlighting the safety of ACT, including doses/dosages
beyond (e.g., 20mg.kg, 20mg.kg LBM, up to 2 g) the typical
therapeutic range described earlier. Despite this, ACT often
receives seemingly unwarranted negative exposure. This is likely
due to a high incident rate of acute liver failure in cases of
overdose, which accounts for 50% of all acute liver failure cases
in the United States (Bunchorntavakul and Reddy, 2013; Yoon
et al., 2016). In these ACT acute liver failure cases, treatment
with ACT antidote N-acetyl cysteine produces low estimated
mortality rates of 0.4% (Bunchorntavakul and Reddy, 2013; Yoon
et al., 2016). Without rapid treatment of an overdose the risk
of acute liver failure and death rises significantly (Blieden et al.,
2014). The minimum acute ACT dose observed to induce acute
liver failure is 125mg.kg body mass (Prescott, 1983). However,
incidents are more commonly observed when doses exceed
250mg.kg body mass [equivalent to 15 g for a 60 kg human
(Prescott, 1983)], far greater than that utilized in recent novel
applied research [20mg.kg LBM up to 1.5 g (Mauger et al., 2010,
2014; Mauger and Hopker, 2012; Foster et al., 2014, 2016, 2017;
Coombs et al., 2015; Taylor et al., 2015)]. From chronic use of
ACT however, there are several incidents of hepatotoxicity from
chronic therapeutic doses but these cases are concomitant with
other drug use, periods of starvation, other illnesses and apparent
allergic reactions (Vitols, 2003). When proposed for use within a
research context and the dose exceeds what is typically considered
therapeutic (1 g), ACT is often treated with non-evidence-
informed scrutiny by ethical review boards. The next section of
this article seeks to summarize existing literature and provide
evidence of safe ACT doses/dosages, their pharmacokinetics and
highlight the minimal risk ACT poses to health within research,
when evidence informed dose/dosages are utilized.
ACETAMINOPHEN DOSE AND
PHARMACOKINETICS
High rates of overdose incidents are likely due to the ease
of access to ACT over the counter, (Bunchorntavakul and
Reddy, 2013; Yoon et al., 2016). Taken orally ACT is rapidly
metabolized in the gastrointestinal tract and then primarily
by the liver into toxic and non-toxic compounds (Hodgman
and Garrard, 2012). Absorption through the gastric mucosa is
negligible but rapid from the small intestine and thus the rate
of absorption is determined by the rate of gastric emptying
(Prescott, 1980). Whilst gastric emptying can be slowed by food
intake the total amount of ACT absorbed over time would not
be affected (Prescott, 1980). The volume of distribution once
in general circulation, in healthy adults, is circa 50 l (Forrest
et al., 1982). Seminal and emerging research provides substantial
evidence that ACT, even administered above the therapeutic
dose (1 g), is safe. Within healthy, and some clinical populations,
doses/dosages up to 2 g acutely and 2 g 4 ∗ daily over multiple
days have been used within research (Forrest et al., 1979; Benson,
1983; Skoglund and Pettersen, 1991; Skoglund et al., 1991; Dippel
et al., 2001, 2003b). The plasma half-life of acute therapeutic (1 g)
and larger doses of ACT (20mg.kg up to 1.5 g) ranges between 1.5
and 4 h in humans, with 95% of the dose excreted via urination
24 h post ingestion as unchanged ACT or conjugated with
glucuronic acid, sulphuric acid, mercapturic acid and cysteine
(Prescott et al., 1971; Forrest et al., 1979, 1982; Prescott, 1980).
Only in those with clinical liver damage is ACT plasma half-
life prolonged up to and in excess of 4 h (Prescott et al., 1971;
Forrest et al., 1979). Typically within clinical trials the zenith in
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plasma concentrations reach 10–25µg/ml 1–2 h post ingestion
(Slattery et al., 1987; Singla et al., 2012). A well-controlled
pharmacokinetic study in healthy individuals saw peak plasma
concentrations of 8–19µg/ml from an individualized dose
(20mg.kg LBM) up to ∼1.5 g (range: 1.019–1.42 g), reached
within 120min of oral ingestion (Foster et al., 2016). If peak
plasma concentrations exceed 300µg/ml liver damage is likely
(Prescott, 1983). If plasma concentrations of 200µg/ml 4 h
post ingestion are seen the risk of developing hepatotoxicity
significantly increases (Bunchorntavakul and Reddy, 2013). To
contextualize, acute therapeutic doses (1 g) or those slightly
larger (20mg.kg up to 1.5 g) produce plasma concentrations of
8–25µg/ml (Rawlins et al., 1977; Slattery et al., 1987; Singer
et al., 1995; Foster et al., 2016). This is some 175µg/ml lower
than that typically associated with a risk of hepatotoxicity
(Bunchorntavakul and Reddy, 2013) and 275µg/ml lower than
the established thresholds for liver damage (Prescott, 1983).
Liver damage in response to therapeutic ACT doses have only
been seen in very specific populations—those who are alcohol
dependent, patients receiving enzyme-inducing drugs and those
with specific infectious diseases such as measles and infectious
mononucleosis (Collins and Starmer, 1995; Zimmerman and
Maddrey, 1995; Prescott, 2000; Aminoshariae and Khan, 2015).
Indeed, doses in the range of 1–1.5 g (when a 20mg.kg LBM
dose is employed) in exercise performance research (Mauger
et al., 2010, 2014; Mauger and Hopker, 2012; Foster et al.,
2014) and 20mg.kg LBM (up to a maximum of 1.5 g) in
thermophysiology literature (Foster et al., 2016, 2017) have
been used, without reported side-effects; not unexpected given
the previous comments regarding plasma ACT concentrations
and liver damage. Indeed, 2 g acute doses (even when repeated
within-day) have been tolerated without liver-related or any
other side-effects (Skoglund and Pettersen, 1991). Despite this,
ACT receives negative reactions when proposed for use within
a research context regarding acute doses outside a range that
is typically considered therapeutic (1 g). Even with evidence
suggesting these are entirely safe (e.g., 20mg.kg, 20mg.kg LBM,
or 1.5 g) provided they are not administered to the clinical
populations outlined above and the fact that such doses have
already been utilized regularly elsewhere (Skoglund et al., 1991;
Dippel et al., 2001, 2003b; Mauger et al., 2010, 2014; Foster et al.,
2014, 2016, 2017).
Whilst no side-effects were reported from acute 2 g (Skoglund
and Pettersen, 1991) and 20mg.kg LBM (up to 1.5 g maximum)
ACT administration (Foster et al., 2014, 2016; Mauger et al.,
2014; Coombs et al., 2015), gastrointestinal damage or liver
necrosis were not quantitatively assessed. However, Benson
(1983), Dippel et al. (2001), Dippel et al. (2003b) and Forrest
et al. (1979) who implemented a range of liver function
tests (aspartate aminotransferase, alanine aminotransferase,
alkaline phosphatase and total bilirubin levels) demonstrated no
liver-related side-effects using similar doses. Chronic dosages
exceeding the therapeutic dose (6 ∗ 1 g/day) over five days in
acute ischemic stroke patients (Dippel et al., 2001, 2003b) saw
six adverse liver events in the ACT and ibuprofen condition and
three in the placebo condition (Dippel et al., 2003b). Overall
adverse events (gastrointestinal damage, pneumonia, progressive
stroke) were seen equally across ACT, ibuprofen and placebo
condition (Dippel et al., 2001, 2003b) and therefore could not be
fully attributed to the treatment with ACT. Furthermore, it must
be emphasized that this data (Dippel et al., 2001, 2003b) is from a
population presenting with pathophysiology (i.e., acute ischemic
stroke) that increases the biomarkers typically associated with
the diagnosis of liver related “adverse events.” For example,
an increase in direct bilirubin is correlated with the severity
of stroke (Pineda et al., 2008; Luo et al., 2012; Muscari et al.,
2014). Indeed, even within patients with stable, mild and severe
chronic liver disease, ACT administration (1.5 g acute, 4 ∗ 1
g/day for 5 and 14 days) has not been shown to exacerbate liver
damage (Forrest et al., 1979; Benson, 1983). Rather prolongation
of the ACT half-life is seen (Forrest et al., 1979; Benson,
1983), which if not accounted for could lead to accumulative
plasma concentrations of ACT beyond thresholds typically
considered “safe” [(e.g., 200µg/ml (Bunchorntavakul and Reddy,
2013)] resulting in inadvertent overdose and thus further liver
damage.
From the evidence presented here the standard therapeutic
dose of ACT (1 g single dose up to 4 g daily every 4–6 h) has
not been reported to induce liver damage (Benson, 1983). Acute
doses up to 1.5 g and dosages up to 6 g/day have been shown to be
safe within clinical (Forrest et al., 1979; Dippel et al., 2001, 2003b)
and healthy athletic populations (Foster et al., 2014, 2016, 2017).
Evidently with such an excellent safety record these dose/dosages
should not be considered a significant risk in research studies.
However, various control/safety measures have been employed
or could be recommended to provide further reassurance of
these albeit small risks for research participants. These could
include: (1) utilization of alcohol use disorder identification test
(AUDIT; as part of participant inclusion criteria for enrolment
onto a research project); (2) breathalyzer use (prior to ACT
ingestion); (3) the satisfactory completion of an ACT risk
assessment questionnaire (Foster et al., 2016, 2017). Following
these processes if the researcher or participant are unsure of
their suitability then medical clearance can be sought. These
recommendations could act to reduce the already minimal risk
of ACT-mediated side-effects in apparently healthy populations.
Their adoption within germane ACT centric research designs
should appease any ethically orientated and/or participant safety
concerns. Indeed, such measures have seen use elsewhere already
(Foster et al., 2016, 2017).
SUMMARY AND CONCLUSIONS
From the evidence presented here ACT does not pose a major
threat to health, particularly compared to the adverse events
seen with NSAID use, unless taken in inappropriate dose/dosages
and/or by certain clinical populations. Experimental controls
have been suggested to reduce the already low side-effect risk
from ACT administration within relevant human experimental
designs. While there is evidence of ACT being beneficial during
exercise, this is within a well-controlled research setting where
interactions with other medication and supplements (NSAIDs,
caffeine, etc.), other common conditions (redistribution of blood
flow, hydration status, diet, etc.) and the intensity of exercise
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are explicitly controlled to ensure the safety of participants.
ACT use during exercise where such robust controls are not
in place must not be advocated, the risk of interaction with
any of the stated factors is not known and may increase the
danger of injury/damage to an individual. ACT may be a useful
tool to explore and validate bio-chemical thermophysiological
mechanisms within afebrile human populations. ACT may
alter heat producing mechanisms via inhibition of COX and
subsequently PGE2, which requires evidence in vivo from
humans in lieu of rodent evidence discussed above. Drugs that
have COX inhibiting mechanisms, are associated with potentially
severe adverse side-effects (Ong et al., 2007) although, ACT
has been shown to have a favorable risk profile compared
to other common COX inhibiting drugs such as NSAIDs,
particularly relative to gut damage (Towheed et al., 2006; Jones
et al., 2015). Given the propensity of exercise stress to induce
endotoxemia, intestinal hypoperfusion, and intestinal cellular
injury/damage (van Wijck et al., 2011; ter Steege et al., 2012;
March et al., 2017), a result of redistribution of blood flow
during exercise compromising the intestinal mucosa wall (Van
Wijck et al., 2012; Yeh et al., 2013), such damage could be
incurred if ACT was to be used during uncontrolled exercise
(i.e., outside of research) within any environment (although
most likely a hot environment). However, no reports of any
adverse effects have occurred thus far in the literature (Mauger
et al., 2014; Coombs et al., 2015). Therefore, the potential
for ACT to cause any intestinal injury must be established
within experimental designs that explore ACT mechanisms
during exercise and/or challenging thermal environments.
The evidence discussed above rationalizes the following two
opinions:
(1) ACT should not be advocated for use within a sporting
context, given the present evidence is from tightly controlled
laboratory studies which do not replicate the multifaceted
physiological, biochemical and environmental perturbations
to homeostasis during sporting performance.
(2) ACT may provide a useful tool in determining fundamental
biochemical thermoregulatory mechanisms in vivo in
humans, when appropriate experimental controls and
designs are employed.
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